The role of Bruton's tyrosine kinase and PI3K p110δ in mutant SHP2-induced juvenile myelomonocytic leukemia
Indiana University-Purdue University Indianapolis (IUPUI) === Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm that lacks effective chemotherapies. Most commonly, patients have gain-of-function (GOF) oncogenic mutations in SHP2, leading to hyperactivation of ERK a...
Main Author: | Deng, Lisa |
---|---|
Other Authors: | Chan, Rebecca, J. |
Language: | en_US |
Published: |
2018
|
Subjects: | |
Online Access: | http://hdl.handle.net/1805/15832 |
Similar Items
-
Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
by: Xianhui Wang, et al.
Published: (2021-07-01) -
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials
by: Begg M, et al.
Published: (2021-06-01) -
PI3K in juvenile myelomonocytic leukemia
by: Goodwin, Charles B.
Published: (2013) -
The origin of Juvenile Myelomonocytic Leukemia : Insights from developmental hematopoiesis
by: Tarnawsky, Stefan Pasichnyk
Published: (2017) -
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01)